IPO News - Biostage announces closing of $8 mn public offering
17/02/2017 12:20
Biostage, Inc., a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced the closing on February 15, 2017 of its previously announced public offering of 20,000,000 shares of common stock and warrants to purchase 20,000,000 shares of common stock, for total gross proceeds of USD 8 million.
The offering was priced at USD 0.40 per share of common stock, with each share of common stock sold with one five-year warrant to purchase one share of common stock, at an exercise price of USD 0.40 per share.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as exclusive placement agent for the offering.
17/02/2017 12:20
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Free Commodity Tips : Join our Whatsapp No : 9094047040
The offering was priced at USD 0.40 per share of common stock, with each share of common stock sold with one five-year warrant to purchase one share of common stock, at an exercise price of USD 0.40 per share.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as exclusive placement agent for the offering.
